Stockscreener 앱 받기
23.35
2.10%
0.48
시간 외 거래:
23.35
전일 마감가:
$22.87
열려 있는:
$22.87
하루 거래량:
391.90K
Relative Volume:
1.14
시가총액:
$841.03M
수익:
$13.00M
순이익/손실:
$-68.87M
주가수익비율:
-10.48
EPS:
-2.2276
순현금흐름:
$-76.68M
1주 성능:
+10.56%
1개월 성능:
-8.00%
6개월 성능:
+20.30%
1년 성능:
+0.00%
1일 변동 폭
$22.43
$23.55
1주일 범위
$21.26
$24.01
52주 변동 폭
$13.88
$33.20
Evommune Inc Stock (EVMN) Company Profile
명칭
Evommune Inc
전화
(650) 223-7745
주소
1891 PAGE MILL RD, PALO ALTO
Compare EVMN vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
EVMN
Evommune Inc
|
23.35 | 823.74M | 13.00M | -68.87M | -76.68M | -2.2276 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Evommune Inc Stock (EVMN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-07 | 재개 | Oppenheimer | Outperform |
| 2026-01-22 | 개시 | Oppenheimer | Outperform |
| 2026-01-08 | 개시 | Raymond James | Strong Buy |
| 2026-01-06 | 개시 | H.C. Wainwright | Buy |
| 2025-12-01 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-12-01 | 개시 | Evercore ISI | Outperform |
| 2025-12-01 | 개시 | Leerink Partners | Outperform |
| 2025-12-01 | 개시 | Morgan Stanley | Overweight |
| 2025-12-01 | 개시 | William Blair | Outperform |
모두보기
Evommune Inc 주식(EVMN)의 최신 뉴스
H.C. Wainwright reiterates Evommune stock rating on trial progress By Investing.com - Investing.com Nigeria
Number of shareholders of Evommune, Inc. – BX:EVMN - TradingView
Evommune (EVMN) Insider Trading Activity 2026 - MarketBeat
Evommune (EVMN) Institutional Ownership 2026 - MarketBeat
EVMN Technical Analysis | Trend, Signals & Chart Patterns | EVOMMUNE INC (NYSE:EVMN) - ChartMill
Analysts’ Top Healthcare Picks: Allogene Therapeutics (ALLO), Evommune, Inc. (EVMN) - The Globe and Mail
RBC Capital Maintains Evommune(EVMN.US) With Buy Rating, Raises Target Price to $50 - Moomoo
Here's Why We're Not Too Worried About Evommune's (NYSE:EVMN) Cash Burn Situation - Moomoo
Evommune (EVMN) Stock Forecast and Price Target 2026 - MarketBeat
TradingKey - TradingKey
Companies Like Evommune (NYSE:EVMN) Are In A Position To Invest In Growth - Yahoo Finance
Morgan Stanley Maintains Evommune(EVMN.US) With Buy Rating, Raises Target Price to $55 - Moomoo
Evommune (NYSE:EVMN) Rating Increased to Hold at Wall Street Zen - MarketBeat
Evommune (EVMN) Earnings Date and Reports 2026 - MarketBeat
Evommune (EVMN) Earnings Decline Versus 85.7% Revenue Growth Tests Bullish Narratives - Sahm
RBC Capital Maintains Evommune(EVMN.US) With Buy Rating, Maintains Target Price $48 - Moomoo
Evommune stock rises 3% on beating first quarter loss estimates By Investing.com - Investing.com Canada
Evommune stock rises 3% on beating first quarter loss estimates - Investing.com
Evommune : Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q) - marketscreener.com
Evommune Highlights Q1 Results and Advancing Inflammation Pipeline - TipRanks
Earnings Flash (EVMN) Evommune, Inc. Reports Q1 Revenue $0K - marketscreener.com
Evommune’s First Quarter 2026 Financial Results and Business Activities Released on StockTitan.net - geneonline.com
Evommune (NYSE: EVMN) updates S-1 with Q1 results and $117M raise - Stock Titan
Evommune, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Evommune (NYSE: EVMN) raises $117M and funds operations into 2028 - Stock Titan
Evommune (NYSE: EVMN) details Q1 2026 loss, cash runway and Phase 2b catalysts - Stock Titan
Evommune Reports First Quarter 2026 Financial Results and Provides Business Highlights - Yahoo Finance
20,702,560 Common Stock of Evommune, Inc. are subject to a Lock-Up Agreement Ending on 5-MAY-2026. - marketscreener.com
Certain Rights of Evommune, Inc. are subject to a Lock-Up Agreement Ending on 5-MAY-2026. - marketscreener.com
Certain Options of Evommune, Inc. are subject to a Lock-Up Agreement Ending on 5-MAY-2026. - marketscreener.com
Wall Street Zen Downgrades Evommune (NYSE:EVMN) to Sell - MarketBeat
Stifel Maintains Evommune(EVMN.US) With Buy Rating, Maintains Target Price $54 - Moomoo
Evommune (NYSE:EVMN) Coverage Initiated by Analysts at Stifel Nicolaus - MarketBeat
Stifel initiated coverage on Evommune with a new price target - Quantisnow
Stifel Initiates Evommune(EVMN.US) With Buy Rating, Announces Target Price $54 - Moomoo
Evommune and BillionToOne climb on trading debut - MSN
Evommune surges on mid-stage trial win for eczema therapy - MSN
Evommune, Inc. (NYSE:EVMN) Receives Consensus Rating of "Buy" from Brokerages - MarketBeat
Evommune, Inc.'s (NYSE:EVMN) Lock-Up Period To Expire on May 5th - MarketBeat
[EFFECT] Evommune, Inc. SEC Filing - Stock Titan
Evommune’s EVO756 Phase 2b Trial: An Emerging Catalyst in Atopic Dermatitis - TipRanks
Evommune (NYSE: EVMN) registers 4.49M shares for resale by investors - Stock Titan
EVMN Options Chain — NYSE:EVMN - TradingView
Oppenheimer Maintains Evommune(EVMN.US) With Buy Rating, Maintains Target Price $50 - Moomoo
Evommune, Inc. Common Stock (NY: EVMN - FinancialContent
EVMN SEC FilingsEVOMMUNE INC 10-K, 10-Q, 8-K Forms - Stock Titan
Evommune Shelf Registration Raises Dilution Questions After Strong Share Gains - Sahm
EVMN Evommune reports wider Q4 2025 loss than analyst projections, shares dip modestly on soft quarterly earnings.Market Hype Signals - UBND thành phố Hải Phòng
Evommune Inc (EVMN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.98%
0.12%
자본화:
|
볼륨(24시간):